Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
15th Nov 20191:10 pmRNSCompletion of the Acquisition of Leadscope
15th Nov 20197:00 amRNSEarnings Enhancing Acquisition of Leadscope
16th Oct 20197:00 amRNSInformatics Update: Progressive Equity Note
1st Oct 201910:20 amRNSHolding(s) in Company
27th Sep 201912:45 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSHalf-year Report
13th Sep 20197:00 amRNSNotice of Results
15th Jul 20197:00 amRNSHalf Year Trading Update
3rd Jun 20195:06 pmRNSDirector/PDMR Shareholding
31st May 20197:37 amRNSHolding(s) in Company
24th May 20195:03 pmRNSDirector/PDMR Shareholding
23rd May 201911:26 amRNSResult of AGM
2nd May 20194:47 pmRNSPosting of Annual Report & Notice of AGM
29th Apr 20197:00 amRNSExercise of Options and Total Voting Rights
26th Apr 201910:59 amRNSHolding(s) in Company
18th Apr 20192:06 pmRNSSecond Price Monitoring Extn
18th Apr 20192:00 pmRNSPrice Monitoring Extension
15th Apr 20196:03 pmRNSHolding(s) in Company
15th Apr 20195:00 pmRNSHolding(s) in Company
12th Apr 20193:46 pmRNSHolding(s) in Company
12th Apr 201911:58 amRNSHolding(s) in Company
12th Apr 201911:52 amRNSHolding(s) in Company
12th Apr 20197:36 amRNSHolding(s) in Company
11th Apr 20199:49 amRNSResult of Secondary Placing
11th Apr 20197:00 amRNSProposed Placing to Sell 1,660,000 Shares
8th Apr 20196:01 pmRNSHolding(s) in Company
4th Apr 20191:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSNotice of Results
1st Mar 20195:50 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSHolding(s) in Company
28th Feb 201910:35 amRNSIssue of Equity and Total Voting Rights
20th Feb 20191:44 pmRNSExercise of Options, PDMR Dealing and TVR
19th Feb 20192:09 pmRNSDirector/PDMR Shareholding
22nd Jan 20197:00 amRNSTrading Update
7th Dec 20183:28 pmRNSHolding(s) in Company
2nd Oct 20187:00 amRNSExercise of Options and Total Voting Rights
24th Sep 20187:00 amRNSHalf-year Report
10th Sep 20187:00 amRNSNotice of Results
6th Aug 20181:39 pmRNSHolding(s) in Company
23rd Jul 20187:00 amRNSTrading Update
6th Jun 20187:00 amRNSContract win
24th May 201810:43 amRNSResult of AGM
16th May 20183:18 pmRNSNotice of AGM
26th Mar 20187:01 amRNSSEND Contract Extension and SEND Update
26th Mar 20187:00 amRNSFinal Results
16th Mar 20187:00 amRNSNotice of Results
12th Mar 20189:33 amRNSIssue of Equity and TVR
7th Mar 20187:00 amRNSSaaS Business Update
26th Feb 20187:00 amRNSGrants to Directors under the Instem LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.